Literature DB >> 18372072

Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors.

Nicolas Sluis-Cremer1, Gilda Tachedjian.   

Abstract

The non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) are a therapeutic class of compounds that are routinely used, in combination with other antiretroviral drugs, to treat HIV-1 infection. NNRTIs primarily block HIV-1 replication by preventing RT from completing reverse transcription of the viral single-stranded RNA genome into DNA. However, some NNRTIs, such as efavirenz, have been shown to inhibit the late stages of HIV-1 replication by interfering with HIV-1 Gag-Pol polyprotein processing, while others, such as the pyrimidinediones, have been shown to inhibit both HIV-1 RT-mediated reverse transcription and HIV-1/HIV-2 viral entry. Accordingly, in this review we describe the multiple mechanisms by which NNRTIs inhibit HIV-1 reverse transcription (and in some cases HIV-2 reverse transcription) and other key steps involved in HIV-1/HIV-2 replication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18372072      PMCID: PMC2745993          DOI: 10.1016/j.virusres.2008.01.002

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  47 in total

1.  Analysis of efficiency and fidelity of HIV-1 (+)-strand DNA synthesis reveals a novel rate-limiting step during retroviral reverse transcription.

Authors:  M Götte; M Kameoka; N McLellan; L Cellai; M A Wainberg
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

2.  Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation.

Authors:  Nicolas Sluis-Cremer; Dominique Arion; Michael E Abram; Michael A Parniak
Journal:  Int J Biochem Cell Biol       Date:  2004-09       Impact factor: 5.085

3.  SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2.

Authors:  R W Buckheit; K Watson; V Fliakas-Boltz; J Russell; T L Loftus; M C Osterling; J A Turpin; L A Pallansch; E L White; J W Lee; S H Lee; J W Oh; H S Kwon; S G Chung; E H Cho
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses.

Authors:  J Ren; J Diprose; J Warren; R M Esnouf; L E Bird; S Ikemizu; M Slater; J Milton; J Balzarini; D I Stuart; D K Stammers
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

5.  Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.

Authors:  N Sluis-Cremer; G I Dmitrienko; J Balzarini; M J Camarasa; M A Parniak
Journal:  Biochemistry       Date:  2000-02-15       Impact factor: 3.162

6.  Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase.

Authors:  G Tachedjian; M Orlova; S G Sarafianos; E Arnold; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

7.  A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors.

Authors:  Dimitrios Motakis; Michael A Parniak
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 8.  TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase.

Authors:  María-José Camarasa; Ana San-Félix; Sonsoles Velázquez; María-Jesús Pérez-Pérez; Federico Gago; Jan Balzarini
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

9.  Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1.

Authors:  Louise Z Wang; George L Kenyon; Kenneth A Johnson
Journal:  J Biol Chem       Date:  2004-07-01       Impact factor: 5.157

10.  The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.

Authors:  Joeri Auwerx; Miguel Stevens; An R Van Rompay; Louise E Bird; Jingshan Ren; Erik De Clercq; Bo Oberg; David K Stammers; Anna Karlsson; Jan Balzarini
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more
  62 in total

1.  N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.

Authors:  Mia J Biondi; Greg L Beilhartz; Suzanne McCormick; Matthias Götte
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

2.  Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.

Authors:  Jiong Wang; Robert A Bambara; Lisa M Demeter; Carrie Dykes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

3.  Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.

Authors:  Mihai V Putz; Nicoleta A Dudaș; Adriana Isvoran
Journal:  Int J Mol Sci       Date:  2015-08-18       Impact factor: 5.923

4.  Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay.

Authors:  Shogo Nakajima; Koichi Watashi; Kento Fukano; Senko Tsukuda; Kousho Wakae; Hideki Aizaki; Masamichi Muramatsu; Takaji Wakita; Tetsuya Toyoda
Journal:  J Gastroenterol       Date:  2019-11-25       Impact factor: 7.527

5.  Efavirenz binding site in HIV-1 reverse transcriptase monomers.

Authors:  Valerie A Braz; Mary D Barkley; Rebecca A Jockusch; Patrick L Wintrode
Journal:  Biochemistry       Date:  2010-11-19       Impact factor: 3.162

6.  Efavirenz stimulates HIV-1 reverse transcriptase RNase H activity by a mechanism involving increased substrate binding and secondary cleavage activity.

Authors:  John M Muchiri; Dongge Li; Carrie Dykes; Robert A Bambara
Journal:  Biochemistry       Date:  2013-07-09       Impact factor: 3.162

7.  Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease.

Authors:  John M Louis; Rieko Ishima; Annie Aniana; Jane M Sayer
Journal:  Protein Sci       Date:  2009-12       Impact factor: 6.725

8.  Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam.

Authors:  Junko Tanuma; Shoko Matsumoto; Sebastien Haneuse; Do Duy Cuong; Tuong Van Vu; Pham Thi Thanh Thuy; Nguyen Thi Dung; Nguyen Thi Hoai Dung; Nguyen Vu Trung; Nguyen Van Kinh; Shinichi Oka
Journal:  J Int AIDS Soc       Date:  2017-12       Impact factor: 5.396

9.  Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain.

Authors:  Martin T Christen; Lakshmi Menon; Nataliya S Myshakina; Jinwoo Ahn; Michael A Parniak; Rieko Ishima
Journal:  Chem Biol Drug Des       Date:  2012-08-31       Impact factor: 2.817

10.  Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.

Authors:  Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.